retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Vitality Medical | Big update in the weight loss world 👏 The FDA has officially approved a new higher-dose semaglutide option, increasing the maximum weekly Oral semaglutide drops - No

Study: Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial

[5] [6] Extensive post-marketing surveillance and clinical trials have not established a causal relationship in humans using these medications

Disclaimer: This blog post is for informational purposes only and does not constitute medical advice

Klinic provides only branded, FDA-approved weight loss drugs, steering clear of compounded formulations

We check in regularly, either in person or virtually, to monitor your progress, fine-tune dosing, and troubleshoot any side effects